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Clinical Question 
Should statin therapy be offered to all patients with type 2 diabetes? 
Evidence-Based Answer 
Based on current evidence, statin therapy should be offered to all patients with type 2 diabetes 
who are known to have coronary artery disease.1,2 [Strength of recommendation: A] 
For patients older than 40 years with type 2 diabetes who are not known to have cardiovascular 
disease, statins are recommended if other cardiovascular risk factors are present, regardless of 
the initial low-density lipoprotein (LDL) level, if the patient has failed to reach the target LDL 
goal of less than 100 mg per dL (2.6 mmol per L) by lifestyle modification for primary 
prevention.1-3 [Strength of recommendation: A] 
There is no clear evidence to support routine use of statins in patients with type 2 diabetes who 
are younger than 40 years, who have no cardiovascular risk factors, and who have an LDL level 
lower than 130 mg per dL (3.4 mmol per L), although that has been suggested by some expert 
groups. [Strength of recommendation: C] 
Evidence Summary 
A recent systematic review and meta-analysis1 identified 14 randomized controlled trials of 
primary and secondary prevention of type 2 diabetes. Six studied primary prevention and eight 
studied secondary prevention (i.e., prevention in patients with known heart disease). All but one 
study in each group used statins. Lipid-lowering agents were more effective than placebo for 
secondary prevention of any cardiovascular event (absolute risk reduction [ARR]: 7%; 95% 
confidence interval [CI]: 3 to 12%; number needed to treat [NNT]: 14 for 4.9 years of treatment) 
(Table 11). This review1 included trials whose participants had diverse pretreatment LDL 
cholesterol levels. Lipid-lowering medications reduced the risk of any cardiovascular event in 
patients with diabetes who did not have known heart disease (ARR: 3%; 95% CI: 1 to 4%; NNT: 
35 for 4.3 years of treatment). 
TABLe 1 
Meta-analysis of Six Trials of Statins for Primary Prevention 
Trials 
CHD event 
rate, 
control group, 
(n/n) 
CHD event rate, 
intervention 
group, (n/n) 
ARR for CHD 
event (%[95% 
CI]) NNT 
Primary Prevention     
AFCAPS/TexCAPS 6/71 4/84 4 (-4 to 12) 27.1 
HHS 8/76 2/59 7 (-1 to 15) 14.0 
HPS 367/1,976 276/2,006 5 (3 to 7) 20.8 
PROSPER 28/205 32/191 -3 (-10 to 4) -32.3 
ASCOT-LLA 46/1,274 38/1,258 1 (-1 to 2) 169.5 
Pooled*   3 (1 to 4) 34.5† 
Secondary Prevention     
4S 44/97 24/105 23 (10 to 35) 4.4 
CARE 112/304 81/282 8 (1 to 16) 12.3 
HPS 381/1,009 325/972 4 (0 to 9) 23.1 
LIPID 88/386 76/396 4 (-2 to 9) 27.7 
LIPS 31/82 26/120 16 (3 to 29) 6.2 
Post-CABG 14/53 9/63 12 (-3 to 27) 8.2 
PROSPER 31/115 38/112 -7 (-19 to 5) -14.3 
VA-HIT 116/318 88/309 8 (1 to 15) 12.5 
Pooled*   7 (3 to 12) 13.8† 
 
CHD = coronary heart disease; ARR = absolute risk reduction; CI=confidence 
interval; NNT = number needed to treat; AFCAPS/TexCAPS = Air Force Coronary 
Atherosclerosis Prevention Study/Texas Coronary Atherosclerosis Prevention Study; 
HHS = Helsinki Heart Study; HPS = Heart Protection Study; PROSPER = 
Prospective Study of Pravastatin in the Elderly at Risk; ASCOT-LLA = Anglo-
Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm; 4S = Scandinavian 
Simvastatin Survival Study; CARE = Cholesterol and Recurrent Events trial; LIPID 
= Long-Term Intervention with Pravastatin in Ischemic Disease trial; LIPS = Lescol 
Intervention Prevention Study; Post-CABG= Post-Coronary Artery Bypass Graft 
trial; VA-HIT = Veterans Administration High-Density Lipoprotein Cholesterol 
Intervention Trial. 
*-Pooled estimates generated by using meta-analysis; for primary prevention, there 
was no heterogeneity between studies, so a fixed-effects model was used; for 
secondary prevention, there was a substantial between-study heterogeneity (P = 
.026), so a random-effects model was used. 
†-For primary prevention, the NNT for benefit is for 4.3 years; for secondary 
prevention, the NNT for benefit is for 4.9 years. 
Adapted with permission from Vijan S, Hayward RA, for the American College of 
Physicians. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: 
background paper for the American College of Physicians. Ann Intern Med 
2004;140:654. 
For primary and secondary prevention, most of the patients came from the Heart Protection 
Study (HPS).2 HPS was the only individual trial that showed a statistically significant benefit for 
primary prevention. HPS was a large randomized, placebo-controlled trial of 5,963 patients with 
type 2 diabetes. Patients ranged in age from 40 to 80 years, had a total cholesterol of at least 135 
mg per dL (3.5 mmol per L), and were treated with simvastatin (Zocor) or placebo for an average 
of 4.8 years (primary prevention was ARR: 5%; 95% CI: 3 to 7%; secondary prevention was 
ARR: 4%; 95% CI: zero to 9%). HPS found similar relative benefit among those whose 
pretreatment LDL cholesterol level was below 116 mg per dL (3.0 mmol per L) to those with a 
higher LDL level.2 The Prospective Study of Pravastatin in the Elderly at Risk trial found a trend 
toward harm regarding primary and secondary prevention, but it was not statistically significant 
in either case.3 The meta-analysis did not report the impact of statin therapy on all-cause 
mortality and cardiovascular mortality because the information was not included in the original 
study. 
The Collaborative Atorvastatin Diabetes Study (CARDS)4 is a recent multicenter, randomized, 
placebo-controlled trial on the primary prevention of cardiovascular disease in patients with type 
2 diabetes that was not included in the above meta-analysis. This study randomized patients with 
type 2 diabetes who were 40 to 75 years of age with at least one other additional cardiac risk 
factor (e.g., hypertension, retinopathy, albuminuria, current smoking) and an entry LDL 
cholesterol level lower than 160 mg per dL (4.1 mmol per L) to either atorvastatin (Lipitor) 10 
mg once daily or placebo. The mean LDL cholesterol level was 117 mg per dL (3.0 mmol per L) 
in the placebo and treatment groups. After a median duration of 3.9 years, ARR = 3.7% of the 
first occurrence of a major cardiovascular event in the treatment group (NNT: 31 for four years, 
P = .001). 
Recommendations from Others 
The American Diabetes Association (ADA) recommends that lipid-lowering therapy be initiated 
with lifestyle intervention in patients with type 2 diabetes and clinical coronary artery disease. 
The primary goal for all patients with diabetes is an LDL cholesterol level lower than 100 mg per 
dL. Furthermore, the ADA recommends that for patients older than 40 years with diabetes, a 
total cholesterol greater than 135 mg per dL, and without overt cardiovascular disease, statin 
therapy should be offered to achieve an LDL level reduction of 30 to 40 percent regardless of 
baseline LDL levels. For patients younger than 40 years without overt cardiovascular disease but 
with additional cardiac risk factors, the addition of pharmacologic therapy to ongoing lifestyle 
modification to reach a target goal of an LDL cholesterol level lower than 100 mg per dL is 
recommended.5 
A recent evidence-based guideline6 from the American College of Physicians recommends that 
lipid-lowering therapy should be used for all patients with type 2 diabetes and known coronary 
artery disease. It also recommends that statins should be used for primary prevention against 
macrovascular complications in all patients with type 2 diabetes and other cardiovascular risk 
factors. 
The National Cholesterol Education Project (NCEP) Adult Treatment Panel III guideline7 
recommends that patients with diabetes and cardiovascular disease should initiate statin therapy 
regardless of baseline LDL cholesterol levels. For patients in this high-risk group, statins are a 
therapeutic option to achieve a low LDL cholesterol level (i.e., lower than 70 mg per dL [1.8 
mmol per L]).7 This recommendation is endorsed by the ADA.7 However, for patients with 
diabetes who have no known cardiovascular disease and an LDL cholesterol level lower than 116 
mg per dL, NCEP recommends that initiation of a lipid-lowering medication should be an option 
based on the clinical judgment of the physician.7 
Clinical Commentary 
Evidence from recent clinical trials has given physicians a new opportunity to reduce 
cardiovascular morbidity and mortality in patients with type 2 diabetes. For patients with type 2 
diabetes, there is compelling evidence for aggressive lipid lowering in addition to tight blood 
pressure and glycemic control with statin therapy. A recent cost-effectiveness study based on a 
cardiovascular disease life-expectancy model with the assumed benefit of statin therapy from the 
Scandinavian Simvastatin Survival Study8 suggests that among men and women with diabetes 
but no cardiovascular disease, lipid therapy with a statin is likely to be as cost-effective as 
treating individuals with cardiovascular disease who do not have diabetes. The study estimated 
the cost ranges from $5,063 to $23,792 per year of life saved.9 Although more evidence is 
needed to support a universal recommendation of statin therapy for all patients with type 2 
diabetes and without clinical cardiovascular disease, it is clear that most patients with diabetes 
probably benefit to some extent from lipid-lowering therapy. 
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